At recent clinical meetings, two firms — Sequenta and Chronix Biomedical — presented data illustrating the distinct next-generation sequencing-based strategies each is taking to monitor minimal residual disease in cancer patients.

At this year's American Society of Clinical Oncology meeting in Chicago, for instance, Chronix researchers co-authored a poster showing that it was possible to track MRD after surgery in women with breast cancer using tumor markers found in blood samples taken prior to surgery.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.

Cancer clinical trial patients settle with Anil Potti and Duke University.

A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.

Two Johns Hopkins researchers discuss the need for evidence-based data analysis.